GlassScriptPhysician profile
Joyce Bea Henry
NPI 1235801960
$1,728.97
in general payments reported to CMS, 2019-2025
33 companies · $721 in 2025
The $721 reported for 2025 was more than what 80% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $58.49 · 2022: $373 · 2023: $319 · 2024: $258 · 2025: $721.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,297.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,297.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $264.30 | 2021-2025 | |
| Amgen INC. | $148.21 | 2022-2023 | Prolia, Evenity |
| Takeda Pharmaceuticals U.S.A., INC. | $116.26 | 2025 | Hyqvia |
| Pfizer INC. | $102.41 | 2021-2025 | |
| Ucb, INC. | $76.87 | 2024-2025 | Briviact, Fintepla, Zilbrysq |
| Biogen, INC. | $71.45 | 2025 | Vumerity, Tysabri |
| Medtronic, INC. | $66.77 | 2024 | Synchromedii, Corevalve Evolut R |
| Mylan Specialty L.P. | $60.24 | 2022 | |
| Lilly USA, LLC | $59.49 | 2021-2025 | Kisunla, Jardiance, Emgality |
| Otsuka America Pharmaceutical, INC. | $58.81 | 2025 | Rexulti |
| Boston Scientific Corporation | $52.09 | 2024 | |
| Alexion Pharmaceuticals, INC. | $51.19 | 2025 | Ultomiris |
| Glaxosmithkline, LLC. | $51.08 | 2022-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Argenx US, INC. | $49.33 | 2024-2025 | Vyvgart Hytrulo |
| Janssen Pharmaceuticals, INC | $43.16 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $42.41 | 2022 | |
| Almatica Pharma LLC | $37.69 | 2022-2024 | Loreev Xr, Teriparatide |
| Neurocrine Biosciences, INC. | $34.93 | 2025 | |
| Merz Pharmaceuticals, LLC | $32.92 | 2025 | Xeomin, Ampyra, Inbrija |
| Smith+Nephew, INC. | $32.62 | 2022 | |
| Eisai INC. | $30.79 | 2025 | |
| Genentech, INC. | $29.29 | 2025 | Ocrevus |
| Csl Behring | $25.57 | 2025 | Hizentra |
| Curonix LLC | $24.05 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Astrazeneca Pharmaceuticals LP | $24.05 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.63 | 2023 | |
| Merck Sharp & Dohme LLC | $20.50 | 2022 | |
| Vertos Medical, INC. | $20.06 | 2024 | Mild Device Kit |
| Edwards Lifesciences Corporation | $19.65 | 2025 | Sapien 3 Ultra Resilia |
| Mallinckrodt Hospital Products INC. | $18.57 | 2025 | Acthar |
| Novo Nordisk INC | $14.88 | 2021 | |
| Baxter Healthcare | $14.13 | 2025 | Hillrom - Monarch Airway Clearance System |
| Idorsia Pharmaceuticals US INC | $13.57 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joyce Henry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.